Savara

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The firm's lead program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Austin, TX.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Austin, TX.

Savara Inc. (NASDAQ:SVRA) shares rallied Tuesday after Piper Sandler initiated coverage of the stock with an Overweight rating and $7 price target.

Savara Stock Rallies: Technical Analysis Levels

The stock price of Savara Inc (NASDAQ: SVRA) has increased by over 30% pre-market. This is why it happened.

SVRA Stock Price Increases Over 30% Pre-Market: Why It Happened

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the closing of its previously announced underwritten public offering of 57,479,978 shares of its common stock, including 11,694,150 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $1.45 per share. In addition, in lieu of shares of common stock, Savara sold to certain investors pre-funded warrants t

Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters' Option

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the pricing of an underwritten public offering of 45,785,828 shares of its common stock at a price to the public of $1.45 per share. As a component of the offering, in lieu of shares of common stock, Savara offered to certain existing investors pre-funded warrants to purchase an aggregate of 32,175,172 shares of common stock at a purchase price of $1.449 per warrant, which represents the

Savara Announces Pricing of Public Offering of Common Stock

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. In addition, Savara is offering to certain investors the right to purchase pre-funded warrants in lieu of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or a

Savara Announces Proposed Public Offering of Common Stock

Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Savara (SVRA) Stock?

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company's pipeline, leadership, and business operations that are being taken to improve alignment of resources and increase our focus on Molgradex in aPAP and the Phase 3 IMPALA 2 trial. “I am grateful for the opportunity to be a part of the Savara team,” said Matt Pauls, Chairman and CEO, Savara. “Over the last few months, we have moved decisively and with urge

Savara Provides Pipeline and Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara Management will participate in virtual fireside chats at the following investor healthcare conferences: Piper Sandler Annual Healthcare Conference: The recorded fireside chat will be available to registered attendees on the Piper Sandler Conference website from today through December 3, 2020. A replay of the event will be available on the Investors page of Savara's website at

Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences

Savara is a rare lung disease company whose lead asset, Molgradex, failed to meet its primary endpoint in the Phase 3 IMPALA trial. Since that time, Savara has met with the FDA and has designed a new Phase 3 trial, IMPALA 2, that capitalizes on the strong points of Molgradex in IMPALA.

Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Matthew Pauls, Chairman and Interim CEO, will be presenting at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 2:55 PM EST/11:55 AM PST. Interested parties can access a live audio webcast on the Investors page of the Savara website at www.savarapharma.com/investors/events-presentations/. Please connect to the Company's website at least 15 minutes

Savara to Present at the Jefferies Virtual London Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2020 and provided a business update. “After recently joining the management team, it's clear that we must focus on three priorities in the near-term,” said Matthew Pauls, Chairman and Interim CEO, Savara. “The first is advancing our lead program, Molgradex in aPAP and the Phase 3 IMPALA 2 trial, as quickly and as safely as we can

Savara Reports Third Quarter 2020 Financial Results and Provides Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CEO) and from the Board of Directors, effective immediately, to pursue other opportunities.

Savara Announces Senior Management Changes

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C.

Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM.

Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results

Savara (SVRA) to halt the ENCORE study on its lead candidate Molgradex, which was meant to treat nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis.

Savara to Stop Study on Molgradex for NTM Lung Infection

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the decision to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory clinical study of Molgradex for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF).

Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF)

Savara has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Savara Enters Oversold Territory

Savara Inc (SVRA) CEO Robert Neville on Q2 2020 Results - Earnings Call Transcript

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2020 and provided a business update.

Savara Reports Second Quarter 2020 Financial Results and Provides Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord Genuity Global Growth Conference on Wednesday, August 12, 2020 at 8:00 a.m.

Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business update on Thursday, August 6, 2020.

Savara to Report Second Quarter 2020 Financial Results and Provide Business Update

Blink Charging

Liquidia Technologies Inc

Navidea Biopharma

Many believe that the market does not accurately the current state of our economy. With double-digit unemployment and Q2 earnings expected to disappoint, the stock market is rich with several Top Shorts for you to hedge out or bet with your portfolio today.

Top Stocks To Short With VIX Rallying

Savara Inc. (SVRA) CEO Rob Neville on Q1 2020 Results - Earnings Call Transcript

Savara has been struggling lately, but the selling pressure may be coming to an end soon.

Savara Sees Hammer Chart Pattern: Time to Buy?

Savara Inc. (SVRA) CEO Rob Neville on Q4 2019 Results - Earnings Call Transcript

News for Savara Stock (SVRA)